Pharmaron Beijing Co., Ltd. (300759.SZ) Stock

About Pharmaron Beijing Co., Ltd.

Pharmaron Beijing Co., Ltd., together with its subsidiaries, operates as a pharmaceutical research and development service platform in North America, Europe, the Mainland China, Asia, and internationally. It operates through five segments: Laboratory Services; Chemical and Formulation Process Development and Manufacturing Services; Clinical Research Services; Macromolecule and Cell and Gene Therapy Services; and Others. The company offers laboratory chemistry and biological science services, including small molecule chemical drugs, oligonucleotides, peptides, antibodies, antimicrobial agents, antibody-drug conjugates (ADCs), and cell and gene therapy products; small molecule CDMO services, such as API process development and production, material science and preformulation, formulation development, and analytical development. It also provides clinical research services; macromolecular and cell and gene therapy services comprising drug discovery, development and production services, cell and gene therapy laboratory services, and gene therapy drug development and production services. In addition, the company is involved in the provision of technology development, technology transfer, technical consultation, technical services, and technical training; import and export of goods and technologies. Pharmaron Beijing Co., Ltd. was incorporated in 2004 and is headquartered in Beijing, the People's Republic of China.

Pharmaron Beijing Co., Ltd. is led by CEO Bo Liang Lou, employs 25,088 people, headquartered in Beijing, CN, publicly traded since 2019.

Pharmaron Beijing Co., Ltd. (300759.SZ) stock trades at $43.11 with a market capitalization of $79.21B. The stock is valued at a price-to-earnings (P/E) ratio of 45.38, price-to-book of 4.83, price-to-sales of 5.19. Over the past 52 weeks the stock has ranged between $21.01 and $53.57, and currently trades 19.5% below its 52-week high. It pays a dividend yielding 0.46%.

On profitability, Pharmaron Beijing Co., Ltd. generates a return on equity (ROE) of 10.11%, an operating margin of 13.40%, a net profit margin of 11.23%.

The balance sheet shows a debt-to-equity ratio of 0.41 — a conservative balance sheet with little leverage risk, a current ratio of 1.02.

300759.SZ has an average daily trading volume of 71,321,141 shares, a beta of 0.69 (less volatile than the overall market), 1.48B shares outstanding.

Official website: www.pharmaron.com